Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
Follow CELU
Celularity, Inc. (CELU) EV/Sales
As of 16 October 2026, Celularity, Inc. (CELU) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 0.0× (June 2021) to 67.8× (April 2022); the current reading is higher than 59% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | 64.29% |
| FY2024 | 1.6× | (68.19%) |
| FY2023 | 5.0× | (56.73%) |
| FY2022 | 11.7× | (26.19%) |
| FY2021 | 15.8× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 4.2× | 58.62% |
| Dec 2025 | 2.6× | 13.45% |
| Sep 2025 | 2.3× | 15.68% |
| Jun 2025 | 2.0× | 22.63% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ANVS Annovis Bio, Inc. compare | n/m |
| ALDX Aldeyra Therapeutics, Inc. compare | n/m |
| DWTX Dogwood Therapeutics, Inc compare | n/m |
| VERU Veru Inc. compare | 1.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | 1.2× |
| CELU Celularity, Inc. | 4.1× |
| SER Serina Therapeutics, Inc. compare | 66.0× |
| GRCE Grace Therapeutics, Inc. compare | 109× |
| TIL Instil Bio, Inc. compare | 401× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)